Mira Marinova

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Patients with heavily pretreated advanced cancer or with rare tumors are difficult to treat. Molecular profiling (MP) of tumors to identify biomarkers that predict potential outcomes with individual therapies is an emerging strategy to guide treatment decisions. Patients with rare tumors for which standard-of-care therapy was unavailable or more common(More)
  • 1